Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Director Christopher D. Alafi bought 1,001 shares of the firm’s stock in a transaction dated Friday, December 29th. The shares were bought at an average price of $14.48 per share, with a total value of $14,494.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of Intra-Cellular Therapies Inc. (NASDAQ ITCI) traded up $0.31 on Thursday, hitting $15.47. The company had a trading volume of 233,500 shares, compared to its average volume of 314,400. Intra-Cellular Therapies Inc. has a 1-year low of $7.85 and a 1-year high of $22.67. The firm has a market cap of $902.17, a price-to-earnings ratio of -7.06 and a beta of 0.72.
Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.06 million. During the same quarter in the prior year, the firm posted ($0.70) EPS. The business’s revenue was up 675.0% on a year-over-year basis. analysts anticipate that Intra-Cellular Therapies Inc. will post -2.13 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in ITCI. Perceptive Advisors LLC acquired a new position in Intra-Cellular Therapies during the 3rd quarter worth approximately $14,667,000. Wasatch Advisors Inc. boosted its position in Intra-Cellular Therapies by 65.1% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock worth $20,611,000 after acquiring an additional 654,400 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Intra-Cellular Therapies during the 3rd quarter worth approximately $8,663,000. Dimensional Fund Advisors LP boosted its position in Intra-Cellular Therapies by 419.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 647,187 shares of the biopharmaceutical company’s stock worth $8,038,000 after acquiring an additional 522,565 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Intra-Cellular Therapies by 336.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after acquiring an additional 447,586 shares during the last quarter. 74.47% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently issued reports on ITCI. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Wednesday. ValuEngine lowered Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Sunday. BidaskClub lowered Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 30th. Canaccord Genuity began coverage on Intra-Cellular Therapies in a research report on Friday, December 15th. They issued a “buy” rating and a $31.00 price objective for the company. Finally, SunTrust Banks upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. Intra-Cellular Therapies has an average rating of “Buy” and an average price target of $25.56.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.